[Monoclonal antibodies associated with chemotherapy as first line therapy in metastatic colorectal cancer: relative efficacy, safety and efficiency]
Castillo Muñoz MA, Ubago Pérez R, Navarro Caballero JA, Márquez Peláez S, Beltrán Calvo C, Flores Moreno S, Rodríguez López R, Romero Tabares A
Record ID 32013000745
Spanish
Authors' objectives:
To evaluate the efficacy of bevacizumab, cetuximab and panitumumab, for the first line therapy in metastatic colorectal cancer, in adult patients who tolerate fluoropyrimidin-based chemotherapy with irinotecan and/or oxaliplatin versus this chemotherapy.
To evaluate the safety of bevacizumab, cetuximab and panitumumab, in metastatic colorectal cancer.
To evaluate the efficiency of each monoclonal antibody (bevacizumab, cetuximab and panitumumab), for the first line therapy in metastatic colorectal cancer, in adult patients who tolerate fluoropyrimidin-based chemotherapy with irinotecan and/or oxaliplatin versus this chemotherapy.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
https://www.aetsa.org/download/publicaciones/antiguas/AETSA_6-2011_MAB_CaColorrectal.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Spain
MeSH Terms
- Humans
- Colorectal Neoplasms
- Antibodies, Monoclonal
- Antineoplastic Combined Chemotherapy Protocols
Contact
Organisation Name:
Andalusian Health Technology Assessment Area
Contact Address:
Area de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Avda. Innovación, s/n Edificio Arena 1. Sevilla (Spain) Tel. +34 955 006 309
Contact Name:
aetsa.csalud@juntadeandalucia.es
Contact Email:
aetsa.csalud@juntadeandalucia.es
Copyright:
Andalusian Agency for Health Technology Assessment (AETSA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.